Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call August 7, 2026 4:30 PM EDT Company Participants Steven Lo - President, CEO & Director James Cummings - Chief Medical Officer Jeroen Grasman - CFO, Principal Accounting Officer & Principal Financial Officer Sean Tucker - Senior VP & Chief Scientific Officer Conference Call Participants David Carey - Finn Partners, Inc. Presentation Operator Greetings, and welcome to the Vaxart Stockholder fireside chat. As a reminder, this conference is being recorded. I would now like to turn the webcast over to David Carey of Finn Partners. David Carey Finn Partners, Inc. Joining us from Vaxart are Steve Lo, Chief Executive Officer; Dr. Sean Tucker, Founder and Chief Scientific Officer; Dr. James F. Cummings, Chief Medical Officer; Jeroen Grasman, Chief Financial Officer; and Ed Berg, Senior Vice President and General Counsel. Before we begin, I would like to remind everyone that during this conference call, Vaxart may make forward-looking statements, including statements about the company's financial results, financial guidance, its future business strategies and operations, any partnerships with third-parties, timing of any anticipated regulatory approvals or that any such approval will be obtained, the company's future cash runway, ability to raise capital, and its product development and regulatory progress, including statements about its ongoing or planned clinical trials. Actual results could materially differ from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process and other risk factors described in the Risk Factors section of Vaxart's most recently filed annual report on Form 10-K and periodic reports filed with the SEC. Vaxart undertakes no obligation to update any forward-looking statements after the date of this call. I'll now turn the call over to Steven Lo.